Evidence map›Paper›PMID 41528889›Full record

ArticleJournal of travel medicine2026

Comment on: Pettersson et al. Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein.

Vianney Tricou, Jill Livengood, Mayuri Sharma, Olaf Zent, Martina Rauscher, Yin Xiang Setoh, Carolina Brünner, Shibadas Biswal, Walid Kandeil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of travel medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vianney TricouVaccine Business Unit, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich), Switzerland.ORCID 0000-0002-5465-8647
Jill LivengoodVaccine Business Unit, Takeda Vaccines Inc., 75 Sidney St, Cambridge, MA 02139,  USA.
Mayuri SharmaVaccine Business Unit, Takeda Vaccines Inc., 75 Sidney St, Cambridge, MA 02139,  USA.
Olaf ZentVaccine Business Unit, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich), Switzerland.
Martina RauscherVaccine Business Unit, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich), Switzerland.
Yin Xiang SetohGrowth & Emerging Markets, Takeda Pharmaceuticals International AG Singapore Branch, 8 Marina Boulevard, #15-01 Marina Bay Financial Centre Tower 1, 018981  Singapore.
Carolina BrünnerTakeda Pharma A/S, Delta Park 45, 2665 Vallensbæk Strand, Denmark.
Shibadas BiswalVaccine Business Unit, Takeda Vaccines Inc., 75 Sidney St, Cambridge, MA 02139,  USA.
Walid KandeilVaccine Business Unit, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich), Switzerland.

Funding

Takeda Pharmaceutical International AG
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

dengueTAK-003vaccine

Identifiers

PMID41528889
PMCPMC13017139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.